Medicalgorithmics

Established in 2005, Medicalgorithmics is a Polish medical technology firm specializing in AI-powered, non-invasive solutions for cardiac arrhythmia diagnostics. The company was founded by Marek Dziubiński and Marcin Szumowski. Dr. Dziubiński, a Ph.D. in digital signal processing and artificial intelligence, was the originator of the company's core technology. His academic work at Gdańsk University of Technology, focusing on signal analysis, laid the scientific foundation for the company's first product. Marcin Szumowski, who served as CEO from 2005 to 2010, leveraged his extensive experience in life science investment and project management to secure initial funding and guide the company through its early commercialization stages, including obtaining the first FDA and CE approvals.

Medicalgorithmics operates on a B2B model, providing its software, AI, and cloud-based solutions to healthcare systems, physicians, and other medical technology companies. Its business strategy has evolved from offering a closed diagnostic system tied to its own hardware to a more flexible model. This includes licensing its AI algorithms as a standalone product and integrating its software with partner devices and IT systems, generating revenue through fees based on the volume of ECG data analyses performed. The company has been publicly traded on the Warsaw Stock Exchange since 2014.

The company's product portfolio is centered around advanced cardiac monitoring and analysis. The flagship PocketECG system is a mobile cardiac telemetry (MCT) device for long-term Holter monitoring that captures and classifies every heartbeat for up to 30 days. This system transmits real-time, full-disclosure ECG data, allowing for remote supervision and quicker diagnostic decisions. A key component of the company's offerings is the DeepRhythm Platform (DRP), a hardware-agnostic, cloud-based software that uses proprietary DeepRhythmAI (DRAI) algorithms for arrhythmia detection and analysis. The platform, which has received both FDA approval and CE certification, is designed to be scalable, serving facilities from small clinics to large hospital networks by automating the diagnostic process and report generation. Another significant product is VCAST (Virtual Cardiac Stress Test), a non-invasive, AI-based system that analyzes CT scan data to assess the significance of coronary artery stenosis, offering an alternative to invasive coronary angiography.

Keywords: cardiac arrhythmia diagnostics, mobile cardiac telemetry, ECG analysis software, artificial intelligence in cardiology, non-invasive cardiac monitoring, Holter monitoring, DeepRhythm Platform, VCAST, PocketECG, remote patient monitoring, digital signal processing, arrhythmia detection algorithms, Warsaw Stock Exchange, medtech, cardiovascular diagnostics, cloud-based healthcare, FDA approved, CE certified, medical imaging analysis, coronary artery disease assessment